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Abstract: Understanding the B cell response to SARS-CoV-2 vaccines is a high priority. Highthroughput sequencing of the B cell receptor (BCR) repertoire allows for dynamic characterization
of B cell response. Here, we sequenced the BCR repertoire of individuals vaccinated by the Pfizer
SARS-CoV-2 mRNA vaccine. We compared BCR repertoires of individuals with previous COVID-19
infection (seropositive) to individuals without previous infection (seronegative). We discovered that
vaccine-induced expanded IgG clonotypes had shorter heavy-chain complementarity determining
region 3 (HCDR3), and for seropositive individuals, these expanded clonotypes had higher somatic
hypermutation (SHM) than seronegative individuals. We uncovered shared clonotypes present
in multiple individuals, including 28 clonotypes present across all individuals. These 28 shared
clonotypes had higher SHM and shorter HCDR3 lengths compared to the rest of the BCR repertoire.
Shared clonotypes were present across both serotypes, indicating convergent evolution due to SARSCoV-2 vaccination independent of prior viral exposure.
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1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent
of Coronavirus disease 2019 (COVID-19) and continues to be a threat to human health
across the globe [1,2]. SARS-CoV-2 mRNA vaccines are effective tools in the fight against
this disease [3,4]. Although there is not a defined correlate of vaccine protection yet,
high levels of SARS-CoV-2 spike neutralizing antibodies have been shown to correlate
with vaccine efficacy [5,6]. While multiple cell types have critical roles in the adaptive
immune response [7], here we focus specifically on the antibody-mediated humoral immune
response to the SARS-CoV-2 vaccine generated in B lymphocytes. Subtle changes in B cell
response can be captured by high-resolution B cell receptor (BCR) sequencing, including
undescribed effects of prior COVID-19 infection on vaccination.
B cells express transmembrane immunoglobulins, otherwise referred to as B cell receptors, which if secreted, recognize antigens as antibodies [8]. Collectively, all BCR sequences
expressed by B cells constitute an individual’s BCR repertoire [9]. Diversity of the BCR
repertoire is created by V(D)J recombination, a process by which genetic variability is
made by altering the usage of gene segments: variable (V), joining (J), and diversity (D)
regions [10]. To fine-tune the humoral immune response, activated B cells can enter germinal centers and undergo affinity maturation, resulting in further diversification. Affinity
maturation involves two broad but related processes: somatic hypermutation (SHM) and
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clonal selection [11]. SHM induces mutations in the variable regions of immunoglobulins, and positive selection occurs for receptors with the highest antigen affinity, resulting
in high-affinity antigen-specific B cell clones [12]. High-throughput sequencing of BCR
repertoires, referred to as BCR-seq, can reveal many dynamic aspects of humoral immune
responses including responses to both infection and vaccination [13].
Analyses of BCR repertoire responses to natural SARS-CoV-2 infection have revealed
increased immunoglobulin isotypes IgA and IgM, and a targeted antibody response to
the entire SARS-CoV-2 spike protein [14]. B cell response to SARS-CoV-2 infection has
also been found to be marked by a slight increase in SHM (IgM/G/A) in the early stages,
then decreasing and remaining low while a dominance of a few high-affinity B cell clones
occurs [15]. Increased COVID-19 disease severity: use of ventilator and even death, has also
been associated with the observation of elevated rates of SHM that do not decrease over
time [16,17]. Meanwhile, in response to mRNA SARS-CoV-2 vaccination, increased isotype
usage of IgG and a narrow SARS-CoV-2 receptor binding domain (RBD) antibody response
have been observed [14]. In contrast to natural infection, SHM rates were not affected by
SARS-CoV-2 vaccination [14], suggesting that differential BCR responses exist between
infection and vaccination. Additionally, recent analyses have revealed common SARS-CoV2 clonotypes present in different individuals, known as public clonotypes [18,19]. These
public clonotypes signify that there is convergent evolution across BCR repertoires, and
that B cell response to COVID-19, across multiple people may occur in a more similar way
than previously thought. Here, we also investigate if convergent evolution occurred in our
dataset and determine if public clonotypes are present. This will allow us to understand
if SARS-CoV-2 vaccination elicits BCR public clonotypes. What is still unclear from these
recent studies is how previous COVID-19 infection could impact BCR repertoire responses
to SARS-CoV-2 vaccination. Characterizing the BCR response to vaccination by previous
exposure will allow us to better understand how and if vaccines employ B cell memory
and allow us to better understand how vaccines work.
2. Materials and Methods
2.1. Individuals and Sample Collection
We enrolled health care workers from our children’s hospital with no known history
of SARS-CoV-2 infection (n = 4, seronegative) and with previous PCR-confirmed SARSCoV-2 infection, 30–60 days prior to this study (n = 5, seropositive). Peripheral blood was
collected prior to vaccination with Pfizer mRNA vaccine (Comirnaty® , Pfizer, New York,
NY, USA) (week 0) and after primary immunization (week 3). All participants received
only one dose of vaccine before BCR analyses. This cohort consisted of 9 individuals
with an average age of 40.78 years, ranging from 28–58 years of age. All individuals
were white, non-Hispanic or Latino, 7/9 were female, and 2/9 were male. Seropositive
group had an average age of 42.4 years, and the seronegative group had an average age
of 38.75 years. The seropositive group was all female, and the seronegative group was
2/4 male and 2/4 female. SARS-CoV-2 vaccine specimens were collected at Children’s
Mercy Kansas City and were reviewed and approved by the Children’s Mercy IRB. Both
plasma and peripheral blood mononuclear cells (PBMCs) were isolated in parallel from the
blood collections and stored in ultra-low temperature freezers until use in antibody titer
quantification and BCR repertoire sequencing, respectively.
2.2. Antibody Titers
To measure antibody levels to the SARS-CoV-2 spike protein subunits, spike subunit
1 (S1), spike subunit 2 (S2), receptor-binding domain (RBD), and nucleocapsid (NP), were
used on a bead-based multiplex assay based on the Luminex (Austin, TX, USA) xMAP
technology (HC19SERG1-85K-04, HC19SERA1-85K-04, HC19SERM1-85K-04, Millipore,
Burlington, MA, USA). Reagent kits with secondary antibodies specific for isotypes IgG,
IgM, IgA were used following the manufacturers protocol. The kit provided a set of SARSCoV-2 antigen conjugated beads (S1, S2, RBD, NP) along with 3 positive control beads
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and a negative control bead set. The positive control beads were coated with different
concentrations of IgG. The negative control beads did not have antigen conjugated to
determine nonspecific binding. The 3 antigen-conjugated beads, 3 positive control beads,
and 1 negative control beads were mixed and incubated with each plasma sample at a
dilution of 1:100 with assay buffer. Samples were run in technical duplicate. To determine
background activity, at least two sample wells per assay plate contained only buffer and
no plasma. PE-anti-human IgG conjugate detection antibody was utilized to determine
antibody response to each SARS-CoV-2 antigen. Using the positive control beads, interassay (plate-to-plate) co-efficient of variation (CV) was determined to be 5.16% for IgG. We
utilized the Luminex analyzer (MAGPIX) and Luminex xPONENT acquisition software
to acquire and analyze data. After acquisition net MFI was calculated by subtracting
background MFI (no plasma).
2.3. RNA Extraction and Library Preparation
Frozen buffy coat PBMC samples derived from partitioned whole blood samples were
processed using the RNeasy Plus Micro Kit (Cat# 74004, Qiagen, Germantown, MD, USA).
Further, 350 ul of RLT buffer was added to buffy coat and lymphocytes were lysed via
pipetting and homogenized with Qiashredder spin columns (Cat# 79656, Qiagen). gDNA
eliminator columns were used to remove genomic DNA following homogenization. The
remaining RNA extraction was carried out according to the RNeasy Plus Micro Kit protocol.
RNA quality and quantity was determined using a nanodrop spectrophotometer (Cat#
13-400-519, ThermoFisher Scientific, Waltham, MA, USA). At least 25 ng of total RNA was
inputted into the Archer BCR Library Prep for each sample. Archer Immunoverse-HS BCR
Protocol for Illumina library prep was performed according to manufacturer instructions
(ArcherDX, Palo Alto, CA, USA). Please see Supplemental Table S1 for depth of sequencing
pre- and post-quality control, RNA concentration at isolation, and number of unique clones
per sample. Quality control procedures were followed as standard by Archer: minimum of
1.5 million reads per sample and 400–600 ng of RNA input, samples that did not follow
this were removed from analysis. Libraries were quantified using the Kappa Library
Quantification Kit (Illumina, San Diego, CA, USA). Libraries were pooled at an equimolar
concentration of 4 nM. Libraries were sequenced on the Illumina MiSeq using 35% PhiX
spike-in to account for low diversity, with the 2 × 300 base pair format.
2.4. Data Analyses
Original raw FASTQ files were obtained using Archer Immunoverse-HS BCR Protocol. FASTQ files were processed through “Archer Immunoverse BCR IGH IGKL v1.0”
pipeline for adaptor trimming and deduplication (Archer, San Jose, CA, USA). Bam file
(sample.molbar.trimmed.deduped.merged.bam) obtained after completion of Archer Immunoverse pipeline was used to generate FASTQ file using samtools v1.10 (Genome
Research Limited, Cambridge, UK). Fastq files for read1 (forward read) and read2 (reverse
read) were created from a single fastq files obtained from merged bam file. Paired-End
reAd mergeR (PEAR v0.9.6, Exelixis Lab, Heidelberg, Germany) was used to merge pair
end reads. Merged pair end reads FASTQ file were converted to FASTA file.
MaskPrimers.py available on pRESTO—The Repertoire Sequencing Toolkit (v0.6.2,
Kleinstein Lab, New Haven, CT, USA) was used for assigning the isotype information for
each read as described in Immcantation portal section “Isotype and Primer Annotations”.
IMGT database was used for V(D)J gene annotations and only the reads with functional
heavy chain were kept for assigning clones and down streaming analysis. Reported
ClonalAbundance, ClonalDiversity and Physicochemical was calculated using Alakazam
(v1.1.0). Shazam (v1.0.2, Kleinstein Lab, New Haven, CT, USA) was utilized for calculating
Mutational count. Default settings were used for samtools and PEAR whereas similar
settings were utilized for running pRESTO, Change-O, Alakazam and Shazam as described
in Immcantation Portal.
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To determine the expanded clone set we thresholded the data by using the 50 most numerous IgG clones by read number for each individual at week 3. See Supplemental Table S2
for top 50 clones at each time point and overlap between time points. Complementaritydetermining region 3 (HCDR3) sequences were queried in the COVID-antibody-database
(Cov-ab-dab) [20].
2.5. Statistical Tests
All statistical tests (t-test, Mann–Whitney, Wilcoxon, Kolmogorov–Smirnov) were
conducted in Prism 9 (Graph Pad, San Diego, CA, USA).
2.6. Data Availability
All sequencing data will be made publicly available through NCBI, accession PRJNA839082.
3. Results
3.1. BCR-seq of Peripheral Blood after COVID-19 Vaccine
We previously determined that antibody titers to SARS-CoV-2 spike protein in response to SARS-CoV-2 vaccination are higher in individuals with a history of recent COVID19 infection (seropositive) when compared to those without (seronegative) [21–24]. From
this dataset, we selected five seropositive and four seronegative individuals for BCR-seq
from weeks 0 and 3 (Figure 1A). Antibody levels of isotypes IgG, IgM, and IgA in blood
plasma from these individuals to SARS-CoV-2 proteins: spike protein 1 (S1), spike protein
2 (S2), receptor binding domain (RBD) and nucleocapsid (NP) were detected with IgG
levels being the highest detected and IgA levels being the lowest (Figure 1B). Generally,
antibody titers were higher for seropositive compared to seronegative at week 0. At week
3, seropositive IgG levels remained higher than seronegative for S1, S2, and NP, but RBD
levels were similar (Figure 1B). At week 3, IgM levels for S2 were higher in seropositive
group, while S1, RBD, NP had no significant differences between groups (Figure 1B). At
week 3, differences in IgA antibody titers between seropositive and seronegative were not
significant for any of the antigens. Overall, these data indicated that within our selected
dataset, similar to previous reports, that COVID-19 infection conferred higher antibody
levels in response to the first dose of vaccine.
3.2. Immunization Did Not Alter the Global BCR Isotype, Variable Gene Usage, or HCDR3
Length Distribution
At baseline before immunization (week 0), IgM sequences had the highest frequency
of isotype for both seropositive and seronegative individuals (seropositive: 66.78%, seronegative: 61.45%), followed by IgG (21.55%, 21.16%), IgD (8.7%, 12.24%), IgA (2.91%, 5.08%),
and IgE (0.06%, 0.07%) (Figure 2A). After a single SARS-CoV-2 immunization (week 3),
no significant changes in isotype usage were observed in the BCR repertoire (Figure 2A).
There were also no differences in isotype usage between seropositive and seronegative
groups at either timepoint.
We then focused on the BCR sequences that contained the IgG isotype as these represented the subclass that had the highest levels in the peripheral blood to SARS-CoV-2
(Figure 1B). First, we analyzed the frequency of the variable gene family (IGHV) usage. IgG
BCR sequences utilized variable gene family 3 (IGHV3) at the highest frequency, followed
by V4, V1, V5, V2, V6, and V7 (Figure 2B). No significant differences were observed in the
frequencies of V gene usage between seropositive and seronegative groups at week 0 or
week 3 (Figure 2B). When we analyzed V gene usage for IgM (Supplemental Figure S1A)
or IgA in BCR sequences (Supplemental Figure S2A) we found similar results, with no
significant differences found in the frequencies of V gene usage between seropositive and
seronegative groups at weeks 0 or 3. These data suggested the total BCR isotype usage and
IgG/M/A V gene usage were similar before and after vaccination and were not different in
individuals infected with COVID-19 before vaccination.
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first dose of vaccine (week 3). We found that a similar proportion of clones that had ≥2
mutations or had <2 mutations at both time points, with no significant difference in proportions between groups (Figure 3A, Supplemental Figures S1C and S2C). Within IgG
BCR sequences with ≥2 mutations, we found that the seronegative group had higher SHM7 of 16
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Altogether, these results indicated modest differences in the frequencies of SHM in the IgG,
IgM and IgA where SARS-CoV-2 vaccination induced increases in SHM in seropositive
group and decreases or results in no change to SHM in seronegative group.
To determine if BCR IgG repertoires were more diverse in response to vaccination we
conducted diversity analyses of the B cell clones using 3 measures: species richness, Shan-
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non diversity index, and Simpson’s diversity index. No statistically significant differences
in species richness, Shannon diversity, Simpson’s diversity were observed for the B cell
clones identified between seropositive and seronegative groups at week 0 (Figure 3C; Mann–
Whitney test; p > 0.9999, Mann–Whitney test; p > 0.9999, Mann–Whitney test; p = 0.6857).
At week 3, there was a trend for BCR clones from the seropositive group to have greater
species richness and Shannon diversity than the seronegative group (Mann–Whitney test;
p = 0.0635, Mann–Whitney test; p = 0.1905). Overall, BCR diversity trended toward being
higher in the seropositive group compared to seronegative group at week 3, after first
vaccine dose.
3.4. Altered Genetic Features of the Most Abundant Clonotypes between Seropositive and
Seronegative Groups
When we examined pre-existing IgG clones in the repertoire at week 3, we found that
the majority of the IgG clone repertoire was made of novel clones (Figure 4D, top panel).
At week 3, for the seropositive group on average 98.2% of the repertoire was made of novel
clones, and for the seronegative group on average 98% clones were novel. Pre-existing IgG
clones in the repertoire at week 3 are minimal (ranging 5.8–0.67%, average seropositive
1.8%, average seronegative 2%). We then selected the 50 most abundant IgG clones as the
most numerous clonotypes based on reads from each sample at week 3. This threshold was
determined by reviewing clonal frequency by reads at week 3 (Supplemental Figure S3) and
referring to previous literature where the most numerous clones within the repertoire were
thresholded and analyzed [16]. There was minimal overlap between top 50 most numerous
IgG clonotypes at week 3 and clones of any isotype at week 0 (Figure 4D, bottom panel).
For seropositive samples, on average 89.6% of the top 50 clones were novel at week 3. For
seronegative samples, on average 74.5% were novel at week 3. This indicated that most of
the top 50 IgG clones at week 3 were novel at week 0. Furthermore, we analyzed the top 50
most abundant IgG clones at week 0 and found minimal overlap with the top 50 IgG clones
at week 3 (Supplemental Table S2). For seropositive, on average 93% of the top 50 at week 0
were not present in week 3 top 50 and for seronegative 95.2% were not present in week 3
top 50. This indicated that very few clones were in the expanded group at both time points.
V gene usage in the top 50 clone groups did not significantly differ from the remaining,
less abundant clones “other” (Figure 4A). Furthermore, we did not observe any significant difference in the IGHV gene usage in the Top 50 clones between seropositive and
seronegative groups.
The average HCDR3 length was statistically significantly shorter in the top 50 group
of BCR clones when compared to all other clones for both seropositive (Mann–Whitney
test, p = 0.0079) and seronegative (Mann–Whitney test, p = 0.0286) groups (Figure 4B).
There were no statistical differences when comparing top 50 HCDR3 length mean groups
between serotypes (Mann–Whitney test; p = 0.2857) (Figure 4B). The distribution of HCDR3
lengths for top 50 was also significantly different when compared to the other clone group
(Supplemental Figure S4; seropositive, Kolmogorov–Smirnov p = 0.0354; seronegative,
Kolmogorov–Smirnov p = 0.0354). Top 50 expanded clones in response to vaccination in
both serotypes had shorter HCDR3 lengths compared to other clones.
SHM was higher in the seropositive top 50 clones (mean 4.044%) when compared to
the top 50 seronegative clones (mean 3.541%; t-test with Welch’s correction; p = 0.0080)
(Figure 4C). Seronegative top 50 clones had lower SHM when compared to other clones
(t-test with Welch’s correction; p = 0.0123) (Figure 4C). No statistically significant difference
in SHM was observed between top 50 clones and other clones in the seropositive group
(Figure 4C). Overall, these data indicated that seropositive expanded clones had higher
SHM than seronegative expanded clones in response to vaccination.
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To investigate whether IgG clones from previous infection were expanded in response
to the vaccine, we determined, within the expanded top 50 clone group, if any of the
clonotypes were present at week 0 before vaccination. When comparing IgG clones from
the whole BCR repertoire at week 3 and to week 0, pre-existing clones only accounted for
1.7% in the seropositive and 3.4% in the seronegative, which was not statistically significant
(Figure 4D, top panel). Usage of pre-existing IgG clones in the top 50 group averaged
12.8% in the seropositive group and 25% in the seronegative group (Figure 4D, bottom
panel). We characterized the top 50 clones at time point 1 and compared to the top 50 at
time point 2 and found little overlap (Supplemental Table S2). We did not see a statistically
significant difference between seropositive and seronegative groups in usage of pre-existing
clones. Both seropositive and seronegative had pre-existing clonotypes that were expanded
in number after immunization, but both repertoires were dominated by novel clones at
week 3 (Figure 4D).
3.5. Convergent Clones Were Observed across Both Serotypes including 28 Clones Present in All
Samples in This Study
We determined shared clone usage based on highly similar HCDR3 sequences present
between two or more individuals and limited our scope to the 50 most numerous clones.
We identified 28 clonotypes that were present across all individuals (n = 9, S1–9) in this
study (Figure 5A). Seven clones were present in two individuals (n = 2). Two clones were
shared between two individuals in three instances (n = 2). One clone was shared across
two individuals in three instances (n = 2), one clone was shared across three individuals in
three instances (n = 3), one clone was shared across four individuals in one instance (n = 4),
and one clone was shared across six individuals in two instances (n = 6) (Figure 5A). No
detectable difference in convergent clones was determined between the serotypes.
We then characterized the properties of the 28 convergent clones that were shared across
all 9 individuals: HCDR3 length, V gene usage, and SHM. No difference was observed between the 28 convergent seropositive (mean = 7.617) and seronegative groups (mean = 7.500)
(t-test with Welch’s correction p = 0.8975). SHM was higher in the 28 convergent clone
groups when compared to the top 50 expanded clone group (t-test with Welch’s correction; p < 0.0001) and the remaining other clones in the repertoire (t-test with Welch’s
correction; p < 0.0001) (Figure 5B). The 28 convergent clone group had the highest SHM
of any clone group observed in this study (convergent 28: 7.4027%; top 50: 3.813%; other
clones: 1.515%). HCDR3 length distribution was different from the remaining other clones
in the repertoire, overall convergent clones had shorter HCDR3 lengths (Kolmogorov–
Smirnov test; p = 0.0004) (Figure 5C). The HCDR3 length distribution was not statistically
different between the 28 convergent and the top 50 expanded groups (Figure 5C). Overall,
the 28 shared clone group had shorter HCDR3 lengths and higher SHM compared to other
groups and convergent clones were present across both serotypes.
3.6. Queried Clonotypes Included Matches to the COVID Antibody Database
To determine whether the convergent and expanded clones identified in this study
were previously identified as COVID-specific clones, we queried the HCDR3 regions of
the top 50 expanded clones from each individual and all convergent clonotypes to the
COVID antibody database [20] (Table 1). We defined a match as greater than or equal to 80%
alignment. We uncovered three matches to the database, including one of the twenty-eight
convergent clones. Clone #34727 matched to antibody S-B8 in the database. This clone had
a HCDR3 length of 10, used V3-11 and SHM was 7.626% (Table 1). The aligned antibody,
S-B8, has reported SARS-CoV-2 neutralizing activity [25]. Clone #13327 aligned 80% to
Fab-368 but was only present in one individual studied. Clone #13327 used V3-74, had a
HCDR3 length of 10, and SHM was 1.670% (Table 1). The antibody Fab-368 also has been
reported as neutralizing to SARS-CoV-2 [26]. Clone #8269 matched to a wide variety of
targets including 100% alignment to: XG001, R121-3G10, R410-3D10, PDI-38, COVA1-27,
H712443+K711941, R259-1F4, CV10, H712427+K71111927, and Shiakolas_53181-5. This
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clone used V4-59, had a HCDR3 length of 6, and a SHM of 0.759% (Table 1). These aligned
antibodies were not reported to have neutralizing activities [27–32]. Clone #8269 also had
83.33% alignment with XG002, R616-1E6, PDI-124, R849-3B4, R849-1F9, PDI-211 (Table 1).
These antibodies also did not have known neutralizing activities [27–29]. Clone #8269 has
some cross-reactivity with SARS-CoV-1, binds the spike protein, and has been isolated from
multiple human SARS-CoV-2 patients and vaccinees [28,33,34]. The short HCDR3 length
of 6 amino acids could play a role in the alignment to multiple BCR sequences. These
results identified three public clonotypes that were previously reported as SARS-CoV-2Vaccines 2022, 10, x FOR PEER REVIEW
of 16
specific in other studies, with two that had SARS-CoV-2 neutralization as 11
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described function.
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across all 9 individuals: HCDR3 length, V gene usage, and SHM. No difference was observed between the 28 convergent seropositive (mean = 7.617) and seronegative groups
(mean = 7.500) (t-test with Welch’s correction p = 0.8975). SHM was higher in the 28 convergent clone groups when compared to the top 50 expanded clone group (t-test with
Welch’s correction; p < 0.0001) and the remaining other clones in the repertoire (t-test with
Welch’s correction; p < 0.0001) (Figure 5B). The 28 convergent clone group had the highest
SHM of any clone group observed in this study (convergent 28: 7.4027%; top 50: 3.813%;
other clones:1.515%). HCDR3 length distribution was different from the remaining other
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Table 1. Features of convergent clones that aligned to public clonotypes.

Clone

Alignment Target

Sequence
Match %

Number of
Individuals
Detected

VDJ Gene

CDR3
Length

Mean SHM %

#34727
#13327
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269
#8269

S-B8
Fab-368
XG001
R121-3G10
R410-3D10
PDI-38
COVA1-27
H712443+K711941
R259-1F4
CV10
H712427+K711927
Shiakolas_53181-5
XG002
R616-1E6
PDI-124
R849-3B4
R849-1F9
PDI-211

80
80
100
100
100
100
100
100
100
100
100
100
83.33
83.33
83.33
83.33
83.33
83.33

9
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

IGHV3-11*06
IGHV3-74*01
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09
IGHV4-59*09

10
10
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6

7.626758896
1.670646982
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973
0.758942973

Neutralizing
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

4. Discussion
To understand how previous SARS-CoV-2 infection impacts the B cell receptor repertoire in response to vaccination, we sequenced and analyzed BCR repertoires of seropositive and seronegative individuals after the first dose of Pfizer COVID-19 mRNA vaccine.
Although both T and B cells have crucial roles in adaptive immunity, our aim was to
characterize cellular responses in B cells to explain differential antibody responses that have
been observed after the first dose of vaccine. Our group and others have demonstrated
that individuals with prior COVID-19 had higher levels of antibodies after the primary
SARS-CoV-2 vaccination [21,23,24,35–38].
Overall, the BCR repertoire after a single SARS-CoV-2 vaccination at week 3 did not
differ greatly based on prior SARS-CoV-2 infection before immunization. At week 0, the
seronegative group had higher SHM compared to the seropositive group, this could be due
to a decreased SHM rate in seropositive group, which has been observed in recently COVID19 recovered individuals [15]. To a small degree, SHM increased in the seropositive group
and decreased or remained the same in the seronegative group. It has been previously
shown that SHM does not change in response to SARS-CoV-2 vaccination [14]. Here, we
observed a decrease (IgG and IgM) or no change (IgA) for the seronegative group, which
is in line with these previous findings. The increase in SHM observed in the seropositive
group could indicate a reactivation and expansion of memory B cells which themselves
have high SHM [15]. Increased SHM in the BCR in response to vaccination after a previous
infection has previously been shown for influenza [39]. Additionally, when looking at
SARS-CoV-2 recovered individuals after immunization, IgG+ memory B cells significantly
increased after the first vaccine dose [40].
Although changes in the frequency of isotype usage have previously been observed in
response to SARS-CoV-2 infection and vaccination, no changes in proportion of isotype
usage were found in this study [14,17,27,41]. Increases in the proportion of IgG have been
observed 25 days post-vaccination [14]. It is possible that a low sample size obscured
seeing a difference in this study, and future studies of larger numbers of individuals should
examine differential isotype usage between seropositive and seronegative individuals
undergoing SARS-CoV-2 vaccination.
We found that the majority of the BCR repertoire at week 3 was made up of novel
clones. Pre-existing clones were only a minority of the most abundant (top 50) IgG clono-
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types detected after vaccination in both serogroups. Furthermore, a minimal number of
IgG clones were shared between top 50 at weeks 0 and 3. This indicated that expansion and
selection of SARS-CoV-2 clonotypes in the seropositive group was not necessarily limited to
pre-existing immunological memory from infection. In fact, expansion of novel clonotypes
in response to vaccination is seen in both serotypes.
We defined and characterized an expanded clone set to include only the most numerous clones within each repertoire. We observed that in the expanded clone set the
seropositive group had significantly higher SHM than the seronegative group. This could
be explained by an expansion of different B cell types. Specifically, higher SHM in the
seropositive group could reflect an expansion of memory B cells. Expansion of plasmablasts
(unmutated B cells with low levels of SHM) containing neutralizing antibodies with close
to germ-line expression patterns (i.e., no mutations) have been observed early in naïve
response to SARS-CoV-2 infection [31]. This could account for the SHM response pattern
observed in the seronegative group. Shorter HCDR3 lengths have been associated with
antigen exposure [42], and memory B cells have shorter HCDR3s [43]. It is possible that
expanded clone groups are made up of more HCDR3s from memory B cells, making the
HCDR3 lengths overall shorter. However, shorter HCDR3 lengths were observed in both
expanded clone groups. It remains to be determined whether the differences in the features
of the expanded clone groups are based on B cell types.
Highly convergent clones were found in our dataset in response to vaccination. These
clones were present across both serotypes, and 28 of these clones appeared in every individual in this study. This suggests similar responses to vaccination across serotypes.
Early clonal convergence in response to SARS-CoV-2 is a feature that has been previously
described in other datasets [18,44]. These 28 convergent clones were unique as a group
and had high levels of SHM and shorter HCDR3 lengths when compared to expanded and
“other” clone groups, respectively. Use of the publicly available COVID antibody database
revealed that three clones from our entire expanded clone set aligned to targets with greater
than or equal to 80% homology of characterized SARS-CoV-2- specific B cells. Two of these
public clonotypes (clone #34727, #13327) were previously found to generate SARS-CoV-2
neutralizing antibodies. The other public clone (clone #8269) had cross-reactivity with
SARS-CoV-1 spike protein but was non-neutralizing. Functional studies of clone #8269
would be of future interest. These findings indicated that public clonotypes were generated
in response to SARS-CoV-2 vaccination.
Overall, our findings show that many features of the BCR repertoire in response to
SARS-CoV-2 vaccination were largely similar in individuals with prior COVID-19 before
immunization compared to seronegative individuals (V gene usage, HCDR3 length, diversity). However, previous infection did impact rates of SHM in response to vaccination.
Specifically, higher SHM was seen in the seropositive expanded clone group after vaccination, perhaps indicating differential B cell maturation states between groups. Despite
higher levels of SHM, individuals with prior infection had a majority of novel clonotypes
expanded after immunization and did not utilize a majority of pre-existing clonotypes
detected at baseline. Lastly, the presence of public clonotypes in our dataset and the public
COVID database, indicated convergent B cell clonal evolution that could be harnessed
across multiple individuals by SARS-CoV-2 vaccination.
The limitations of our study are that a small sample size was used, and that the majority
of samples were from white, middle-aged females. Further study into the BCR repertoires
post-primary vaccination, of other ethnicities, ages, and creating an expanded sample size
would be of interest. Another limitation of this study is that expanded clonotypes are not
antigen specific, we determined “expanded or “vaccine-induced” based on the number of
reads at week 3. While the expansion of the clonotypes is likely to reflect their importance
during vaccination, they may not be specific to SARS-CoV-2 vaccination response. Further
confirmation of antigen specificity of these vaccine-induced/expanded clonotypes could
be done to confirm their status.
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